Ginkgo biloba extracts (GBE) inhibited MDR Protein in tamoxifen-resistant MCF-7 human breast cancer cell

Program: Abstracts - Orals, Featured Poster Presentations, and Posters
Session: SAT 292-325-Breast & Prostate Cancer
Saturday, June 15, 2013: 1:45 PM-3:45 PM
Expo Halls ABC (Moscone Center)

Poster Board SAT-311
Min Sun Yi*1, Mi Jie Kim1, Seung Min Oh2 and Kyu Hyuck Chung1
1Sungkyunkwan University, Suwon, South Korea, 2Hoseo University, Asan, South Korea
Tamoxifen, the most commonly used selective estrogen receptor modulator (SERM) for breast cancer patients, has been effective medicine. However, overexpressed multiple drug resistant proteins (MDR proteins), the efflux pumps driving drugs out of the cells, caused tamoxifen resistance.
Flavonoids like phytoestrogens have been reported to inhibit MDR protein-mediated drug resistance. Among them, Ginkgo biloba extracts (GBE) have shown anti-oxidant and anti-angiogenesis properties as well as the effects of selective estrogen receptor modulators (SERM) in previous studies.
In order to investigate GBE treatment could also be an MDR protein inhibitor to overcome tamoxifen resistance by downregulating p-gp, BCRP, and MRP1, Tamoxifen-resistant MCF-7 was used. As a result, GBE downregulated the protein s of p-gp, BCRP and MRP1. Also, GBE showed inhibitory effects of Tamoxifen resistant breast cancer cell growth by inducing apoptosis. In conclusion, GBE could function as an MDR protein inhibitor in breast cancer therapy.

Nothing to Disclose: MSY, MJK, SMO, KHC

*Please take note of The Endocrine Society's News Embargo Policy at